72/100 · Elevated
Manufactured by Roerig
Gliptizide Adverse Events Show High Seriousness and Diverse Reactions
115,301 FDA adverse event reports analyzed
Last updated: 2026-05-12
GLIPIZIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Roerig. Based on analysis of 115,301 FDA adverse event reports, GLIPIZIDE has a safety score of 72 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for GLIPIZIDE include BLOOD GLUCOSE INCREASED, NAUSEA, DRUG INEFFECTIVE, DIARRHOEA, FATIGUE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for GLIPIZIDE.
Glipizide has a safety concern score of 72 out of 100, placing it in the elevated concern category based on analysis of FDA adverse event data. The FDA has received approximately 115,301 adverse event reports for this medication, which is primarily manufactured by Roerig.
The most commonly reported adverse events include Blood Glucose Increased, Nausea, Drug Ineffective. Of classified reports, 56.1% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. Gliptizide reports show a high percentage of serious adverse events (56.1%).
The most common reactions include nausea, dizziness, and hypoglycemia. There is a notable diversity in reported reactions, indicating a wide range of potential side effects.
Patients taking Glipizide should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Gliptizide can interact with other drugs, and patients should be cautious about dose omissions, which can lead to hypoglycemia. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Glipizide received a safety concern score of 72/100 (elevated concern). This is based on a 56.1% serious event ratio across 59,527 classified reports. The score accounts for 115,301 total adverse event reports and 100 distinct reaction types. This elevated score indicates a notable proportion of serious adverse events and warrants careful monitoring.
Adverse event reports by sex: Female: 28,600, Male: 27,522, Unknown: 149. The most frequently reported age groups are age 70 (1,310 reports), age 67 (1,252 reports), age 65 (1,242 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 59,527 classified reports for GLIPIZIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Gliptizide can interact with other drugs, and patients should be cautious about dose omissions, which can lead to hypoglycemia.
If you are taking Glipizide, here are important things to know. The most commonly reported side effects include blood glucose increased, nausea, drug ineffective, diarrhoea, fatigue. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Monitor blood glucose levels regularly to prevent hypoglycemia. Be aware of potential drug interactions and inform your healthcare provider of all medications you are taking. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
Regulators are monitoring the drug closely due to the high number of serious adverse events, particularly related to cardiovascular and renal issues.
The FDA has received approximately 115,301 adverse event reports associated with Glipizide. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Glipizide include Blood Glucose Increased, Nausea, Drug Ineffective, Diarrhoea, Fatigue. By volume, the top reported reactions are: Blood Glucose Increased (6,675 reports), Nausea (4,443 reports), Drug Ineffective (3,505 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Glipizide.
Out of 59,527 classified reports, 33,423 (56.1%) were classified as serious and 26,104 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Glipizide break down by patient sex as follows: Female: 28,600, Male: 27,522, Unknown: 149. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Glipizide adverse events are: age 70: 1,310 reports, age 67: 1,252 reports, age 65: 1,242 reports, age 72: 1,236 reports, age 68: 1,219 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Glipizide adverse event reports is Roerig. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Glipizide include: Weight Decreased, Dizziness, Dyspnoea, Blood Glucose Decreased, Vomiting. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Glipizide to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Glipizide has a safety concern score of 72 out of 100 (elevated concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. Gliptizide reports show a high percentage of serious adverse events (56.1%).
Key safety signals identified in Glipizide's adverse event data include: Hypoglycemia and other serious conditions like myocardial infarction and renal failure are key safety signals.. Drug interactions and dose omissions are frequent, highlighting potential risks.. Serious adverse events such as death and chronic kidney disease are reported.. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Gliptizide can interact with other drugs, and patients should be cautious about dose omissions, which can lead to hypoglycemia. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Glipizide.
Monitor blood glucose levels regularly to prevent hypoglycemia. Be aware of potential drug interactions and inform your healthcare provider of all medications you are taking.
Glipizide has 115,301 adverse event reports on file with the FDA. The most common reactions include nausea, dizziness, and hypoglycemia. The volume of reports for Glipizide reflects both the drug's usage level and the vigilance of the reporting community.
Regulators are monitoring the drug closely due to the high number of serious adverse events, particularly related to cardiovascular and renal issues. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Roerig and compare their safety profiles:
The following drugs share commonly reported adverse reactions with GLIPIZIDE:
Drugs related to GLIPIZIDE based on therapeutic use, drug class, or shared indications: